EL7.AI
StocksMedium•17 November 2026•
4 min read

Marker Therapeutics Posts Adjusted Loss of $0.10 per Share and Revenue Below Estimates

Key Facts

1Adjusted loss was $0.10 per share, compared with an estimate of $0.12, for a positive earnings surprise of 16.67%.
2Revenue was $1.29 million, 47.23% below the consensus estimate.
3Cash, cash equivalents and restricted cash totaled $9,427,758 on September 30, 2026, compared with $17,042,847 on December 31, 2025.
4The company estimated that its resources would last through the second quarter of 2027 without additional grants; funding could extend beyond the fourth quarter of 2027 if it succeeds in raising capital and securing additional grants.

Marker Therapeutics posted an adjusted loss of $0.10 per share for the quarter ended in September 2026, below the $0.12 loss forecast by Zacks consensus, delivering a positive earnings surprise of 16.67%. Zacks published the figures on November 16, while the company filed its quarterly report with the U.S. Securities and Exchange Commission on the same day for the period ended September 30. Performance was mixed, however, as revenue missed estimates by a wide margin. Revenue was $1.29 million, 47.23% below the consensus estimate. The result reflects a better-than-expected loss per share alongside a clear shortfall in quarterly revenue.

Net loss under generally accepted accounting principles was $1,844,472 in the third quarter, compared with $1,998,662 in the same period of 2025. The company said in its report that the narrower loss was mainly due to lower research and development costs. Quarterly research and development expenses fell 7% to $2.2 million. The company attributed a $0.1 million decline to lower clinical trial expenses. Total operating expenses also fell 4% to $3.2 million, compared with $3.4 million a year earlier. This places lower research spending at the center of the year-over-year improvement in the quarterly loss.

The company’s quarterly revenue consists mainly of research grants, rather than product sales or licensing. Total grant revenue was $1,292,996 in the third quarter of 2026, compared with $1,232,938 in the same period of 2025. The amounts recorded included $621,145 from the SBIR NHL grant and $358,391 from the Decoy grant. The company said in its report that it has generated no revenue from selling or licensing its therapeutic candidates since its founding, and that its limited grant income goes toward funding research. Revenue reported by Zacks was $1.29 million, compared with $1.23 million a year earlier, but remained 47.23% below analyst consensus.

In the first nine months of 2026, research and development expenses fell 33% to $6,491,151 from $9,658,322 in the same period of 2025. General and administrative expenses, by contrast, rose 3% to $3,431,002 from $3,338,200. Total operating expenses fell 26% to $9,922,153 from $13,449,657. Net loss for the period narrowed 35% to $6,849,979, compared with $10,460,410 a year earlier. The figures show that cuts to research spending outweighed the increase in administrative expenses during the period.

Cash, cash equivalents and restricted cash totaled $9,427,758 on September 30, 2026, compared with $17,042,847 on December 31, 2025. Working capital also fell to $10,502,879 from $16,796,814 over the same period. The company used $7,615,089 in cash in operating activities during the nine months ended September 30 and recorded no cash from financing activities. It said limited recurring revenue and operating cash losses raise substantial doubt about its ability to continue as a going concern, despite preparing its financial statements on a going-concern basis. It estimated that its current resources would fund operating expenses and capital spending through the second quarter of 2027, assuming no additional grants are received.

The company said it is evaluating additional capital raises and applying for grants, steps that could extend funding beyond the fourth quarter of 2027, although there is no guarantee they will succeed. In September 2026, it received notice of a $2.6 million grant from the U.S. Food and Drug Administration to support a Phase 1 clinical study of its experimental MT-601 therapy in patients with locally advanced, unresectable pancreatic cancer. The company describes itself as clinical-stage and focuses on developing and commercializing T-cell-based immunotherapies for hematological and solid tumors. It said Baylor College of Medicine conducted seven exploratory clinical trials of the technology, in which more than 150 patients were treated. Its candidates include MT-601 for lymphoma and pancreatic cancer, and off-the-shelf MT-401-OTS for acute myeloid leukemia or myelodysplastic syndromes. MRKR shares closed at $0.87 on November 13, 2026.

Open on chart